Nuvaira

Nuvaira is a clinical-stage medical device company pioneering a novel, interventional approach to treating COPD. Its core technology, the dNerva System, delivers radiofrequency (RF) ablation to pulmonary nerves via bronchoscopy, aiming to create a durable 'always-on' bronchodilator effect. The company is advancing this therapy through a robust clinical development program, with data suggesting improvements in lung function, reduction in exacerbations, and decreased breathlessness for a targeted COPD patient population. Nuvaira operates as a private entity, positioning its one-time procedural therapy as a potential complement or alternative to lifelong inhaled medications.

Catheter-based bronchoscopic system using radiofrequency (RF) ablation with proprietary DualCool simultaneous airway and esophageal cooling technology to perform Targeted Lung Denervation (TLD).

Competes against entrenched pharmaceutical therapies (LAMA/LABA inhalers) and other interventional bronchoscopic procedures for severe COPD/emphysema (e.g., endobronchial valves, coils). As a first-in-class neuromodulation approach, it faces the challenge of establishing a new treatment category but may have limited direct device competitors initially.